| ID | 10204 |
| Vaccine Name | HPIV3-EBO-Z ( HPIV3-EbovZ GP Vaccine) |
| Disease Name | Ebola |
| Disease Classification | Hemorrhagic |
| Virus Name | Zaire ebolavirus |
| Nucleic Acid Content | negative-sense, single-stranded RNA |
| Vaccine Type | Virus like particle |
| Vaccine Status | Phase 1 |
| Manufacturer | Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health |
| Year of Manufacturing | 2015 |
| Manufacturing Country | USA |
| Age | 18 - 50 years |
| Dosage | NA |
| Administration Route | Intranasal |
| Adjuvant | NA |
| Target Strain | Zaire Ebola virus glycoprotein |
| Description | Live-attenuated human Parainfluenza virus type 3 vectored vaccine expressing Ebolavirus Zaire glycoprotein |
| Approving Organisation | NA |
| Collaborating Organisation | National Institute of Allergy and Infectious Diseases |
| Other Countries | NA |
| Trade Name | NA |
| PMID | 27764560 |
| Clinical Trial ID | NCT02564575 |
| Reference Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/ |
| Additional Links | NA
|